Biosimilars have been available in the European Union (EU) since 2006. However, their uptake in routine care is heterogeneous across countries. The aim of the present study was to compare the safety information of biosimilars and their originators based on the information in the European risk management plan (RMP).
Introduction
A biological medicinal product is one whose active substance is made by or derived from a living organism. They are often used to treat severe diseases, considering indications from hormonal deficiencies to cancer [1] [2] [3] [4] [5] . Their importance can also be perceived in the rise of research and design expenditures for biologicals by pharmaceutical companies [4] .
While the manufacturing process for small molecule drugs relies on predictable synthetic chemical processes, biological medicinal products are produced in living cell cultures. Owing to the complexity of the production process, it is hard to produce identical batches for biological medicinal products. Nevertheless, lot-to-lot variations do not necessarily translate into clinically relevant differences among batches [6] . Their biological nature, however, may result in the triggering of an immunogenic effect more frequently than with small molecules [7, 8] . Moreover, to understand the difficulty in predicting the immunogenic potential of a biological medicinal product, it is important to note that the manufacturing process itself depends on a variety of parameters that may influence the immunogenicity. Such parameters include the cell line, growth media and conditions, as well as the post-translational modification of the biomolecule [3] .
In October 2005, the European Medicines Agency (EMA) released a guideline for the production of a specific type of biological medicinal product, so-called biosimilars [9] . Biosimilars are officially approved as similar products to a biopharmaceutical originator, which often share the same International Nonproprietary Name (INN) [10, 11] . This indicates that biosimilars and originators contain the same active substance and therefore exert the same therapeutic effect [11] . In the European Union (EU), a biosimilar should be compared with its originator through a comparability exercise to demonstrate 'biosimilarity' [12] . Subsequently, the clinical efficacy for one indication may be extrapolated to (all) other indications for which the originator is authorized after a case-by-case evaluation [13] [14] [15] .
With the introduction of biosimilars into the European market, more resources may be available to allocate to national healthcare services for innovative interventions [14, 16, 17] . Patterns of biosimilar use in Europe vary widely between countries, although a growth in their uptake has been documented recently, especially for filgrastim and epoetin alfa [18] [19] [20] . However, clinicians remain sceptical about using biosimilars instead of originators in naïve patients, as well as about substituting an originator with its biosimilar in patients already successfully treated [14, 16, [21] [22] [23] . The cautiousness is also seen in the United States, where they have been struggling for a framework themselves [24] . Efforts to communicate evidence on biosimilars in order to overcome information gaps led the EMA to publish an information guide for healthcare professionals, to provide them with reference information on the science and regulation underpinning the use of biosimilar medicines. This document clarifies that 10 years of clinical experience with biosimilars has shown them to be as safe and effective in all their approved indications as other biological medicines [25] . Barriers identified for the low uptake of biosimilars include the lack of comparative effectiveness and safety data in the real-world setting, the potential difference in immunogenicity, and uncertainty about data extrapolation to other indications [14, 26] .
The available safety data reported in the documents filed for regulatory purposes at the EMA represent an important source of evidence. The European risk management plan (RMP) contains relevant safety information for each specific product, with a characterization of potential and identified risks alike, including data from real-life data. It represents an overview of a product's safety profile, being systematically updated, and could therefore provide an early indication of differential safety profiles between originators and related biosimilars.
The present study aimed to compare the consistency of safety information reported in the RMP of biosimilars with that available for their originators through publicly available regulatory documents. considered for inclusion in the analysis should have been authorized via the EMA centralized procedure during the timeframe 1 January 2005 to 30 October 2015. The corresponding originators were indicated in the European public assessment report (EPAR) for each biosimilar.
Data sources
A safety concern was defined as an 'identified risk', a 'potential risk' or 'missing information' listed in the summary of the RMP, and in the documents published after authorization called 'Procedural steps taken and scientific information after authorization' (see Box 1 for further details).
Box 1
Regulatory milestones and documents aimed at improving transparency and safety information for the biological medicinal products. Product-specific scientific guidelines have been established for recombinant human insulin, somatropin, recombinant granulocyte colony-stimulating factor, recombinant erythropoietins, monoclonal antibodies and recombinant follicle-stimulating hormone. July 2012: The establishment of the Pharmacovigilance Risk Assessment Committee (PRAC), which assesses all aspects of the risk management of medicines for human use. One of the responsibilities of the PRAC is to support the marketing authorization holder (MAH) with evaluating the safety profile of their product by preparing recommendations on potential risks and the ascertainment of them. Dec 2012: All marketing authorization applications for biosimilars need to include a risk management plan (RMP). Mar 2014: The EMA publishes the summaries of RMPs of centrally authorized drugs.
The Summary of Product Characteristics (SmPC) is a document in which medicinal product information collected through the course of authorization is summarized, containing: pharmaceutical quantitative and qualitative information; efficacy data; safety issues; pharmacological properties and particulars; and MAH information
The RMP is a document in which the safety profile of a drug is reflected, and presents the actions that the MAH will take to improve the safety profile. In the RMP, the safety concerns of drugs are categorized as 'identified risks', 'potential risks' or 'missing information'.
• Identified risks: Established adverse events that have been reported significantly during clinical trials or after marketing authorization.
• Potential risks: Expected risks based on the mechanism of action, but have not been reported significantly during clinical trials or after marketing authorization.
• Missing information: Lacking information about the effect on specific types of patient populations. Examples of missing information include populations not studied or where there is a high likelihood of off-label use. Specific types of population can range from patients from certain age groups to patients with comorbidities.
The document 'Procedural steps taken and scientific information after authorization' contains the outcomes of safety profile evaluations and other important information acquired about the drug during its life cycle (e.g. changes in the manufacturing process).
When the RMP of an originator was not publicly available (i.e. those originators authorized through the mutual recognition procedure or decentralized procedure), the Summary of Product Characteristics (SmPC) was used. We assumed that sections 4.4 (Special warnings and special precautions for use) to 4.8 (Undesirable effects) of the SmPC should have contained all information on safety concerns, as reported in the RMP [27] .
The SmPCs were obtained from the electronic Medicines Compendium (eMC) [28] . The eMC is a licensed database of product information (SmPCs and patient information leaflets) for medicines registered in the UK. The documents available on the eMC are originally approved by the EMA and the UK Medicines and Healthcare Products Regulatory Agency (MHRA), so they can be considered generalizable to the EU member states.
Data analysis
Two principal comparisons were carried out: (i) RMP biosimilar-RMP originator (whenever the RMP was available for both of them); (ii) RMP biosimilar-SmPC originator (in cases where the RMP of the originator was not available). The heterogeneity in the descriptions of safety concerns across regulatory documents was harmonized by grouping similar and related single safety concerns into a unique general safety concern favouring the highest possible homogeneity across different types of events (see Appendix I for more details). No analyses were performed on the basis for the original classification (i.e. 'identified risk', 'potential risk' or 'missing information'), because safety concerns may evolve over time, e.g. are considered a potential risk at the time of approval of the originator and later on become an identified risk.
The originator was compared with its registered biosimilars on a qualitative level (i.e. based on the presence or absence of a general safety concern) and on a quantitative level (i.e. counting the various safety concerns contained for each general safety concern). To evaluate the clinical relevance of safety issues, the general safety concerns were classified as low, medium or high clinical relevance by two of the authors separately (L.R.A.L. and F.T.); disagreements were resolved by discussion, and consensus was eventually sought with a third author (F.R.). Overall, the criteria adopted for categorizing clinical relevance were as follows: (i) nonspecific terms that described nonspecific and broad safety issues (e.g. long-term use, interaction with other drugs), medication errors and safety in specific patient populations (e.g. use in pregnancy) were classified as issues of low clinical relevance; (ii) less specific, reversible and nonfatal general safety concerns were classified as issues of medium clinical relevance (e.g. splenic complications, lack of efficacy, immunogenicity); (iii) life-threatening, unexpected and irreversible general safety concerns were classified as issues of high clinical relevance (e.g. neoplasms, diabetes, interstitial lung disease).
A third comparison -i.e. SmPC biosimilar vs. SmPC originator -was performed as a sensitivity analysis revealing if essential differences specified as Medical Dictionary for Regulatory Activities (MedDRA) terms had been missed in the previous comparisons.
The descriptive analyses of the study were conducted using Microsoft Excel, to calculate the cumulative numbers of safety concerns, general safety concerns and related percentages.
Results
A total of 25 biological medicinal products (19 biosimilars and six originators) were included in the analysis (Table 1) . Overall, seven different types of active substances (as INNs) were included. Epoetin-zeta (Silapo and Retacrit) demonstrated biosimilarity to Eprex (epoetin-alfa), and so were included in the comparison as biosimilars of epoetin-alfa. The first biosimilar was approved in April 2006 (Omnitrope, somatropin), the last in September 2014 (Accofil, filgrastim; and Abasaglar, insulin glargine). The summary of the RMP was retrieved for all biosimilars and two originators (Remicade, infliximab and Lantus, insulin glargine). For the remaining four originators (Genotropin, somatropin; Neupogen, filgrastim; Eprex, epoetin alfa; and Gonal-f, follitropin-alfa), the SmPC was used for the comparison.
Overall, 142 safety concerns were retrieved, corresponding to 55 general safety concerns ( Table 2 ). The degree of clinical relevance was classified consistently by the authors for 49 general safety concerns, while for the remaining six general safety concerns consensus was reached after discussion. Twenty-two (40%) general safety concerns were classified as being of high clinical relevance, 21 (38%) of medium clinical relevance and 12 (22%) of low clinical relevance. Somatropin presented the largest proportion of highly clinically relevant general safety concerns, whereas insulin glargine presented the lowest proportion.
In the case of the INNs insulin glargine and infliximab, we were able to compare the RMPs of biosimilars with those of the originators (Figure 1A ,B; see Appendix IIa for details on single medicinal products). The regulatory safety information for the insulin glargine biosimilar (Abasaglar) and originator (Lantus) were highly similar on a qualitative and quantitative level: only one out of six general safety concerns differed ( Figure 1A) . 'Missing information' on the 'use in children younger than 2 years' (low clinical relevance) was presented in the RMP of the biosimilar insulin glargine but not in the RMP of the originator.
More differences emerged when comparing the infliximab originator with its biosimilars ( Figure 1B) . On a qualitative level, two of the 14 general safety concerns included in the RMP of the originator (Remicade) (i.e. 'interstitial lung disease' and 'interaction with drugs', of high and low clinical relevance, respectively) were not mentioned in the RMP of the biosimilars. However, the RMPs of the biosimilars presented three general safety concerns -i.e. 'bowel obstruction', 'haematological reactions' and 'lack of efficacy' (all of medium clinical relevance) -that were not mentioned in the RMP of the originator. The quantitative comparison for highly clinically relevant safety concerns showed that the RMP of the infliximab originator (Remicade) listed four types of 'autoimmune events' (i.e. 'Stevens-Johnson syndrome', 'toxic epidermal necrolysis', 'erythema multiforme' and 'dermatomyositis') and three types of 'infections' (e.g. 'invasive fungal infections', 'parasitic infections' and 'viral infections') more than the RMP of its biosimilars. The RMPs of the biosimilars listed three types of neoplasm (e.g. paediatric malignancy, leukaemia and colon carcinoma) more than the RMP of the originator.
For other INNs -i.e. erythropoietins, filgrastim, follitropin-alfa and somatropin -the RMP of the biosimilars was compared with the SmPC of the originator ( Overall, the safety profiles of the biosimilars and their originators were highly similar (Figure 2A-D) . In the case of erythropoietins, there were no differences at all between Eprex and its biosimilars when the comparison was conducted at both a qualitative and quantitative level. The RMP of the biosimilars of filgrastim presented only one (out of 15) general safety concerns more than their originator, defined as being of low clinical relevance (i.e. 'general safety and long-term use'). Similarly, the RMP of follitropin-alfa biosimilars had only one (out of 10) additional general safety concern compared with the originator -i.e. 'use in women older than 40 years' (of low clinical relevance). In the somatropin comparison, the RMP of the biosimilar presented one additional highly clinically relevant safety concern ('intracranial vascular disorders') compared with the originator.
Considering the quantitative level comparing highly clinically relevant terms, few differences were noted. Filgrastim biosimilar RMPs presented the safety concern 'cytokine release syndrome', which was not present in the SmPC of the originator; however, the safety concern 'capillary leak syndrome' (considered strongly related to 'cytokine release syndrome') was reported for both the originator and biosimilars. At the quantitative level, the comparison of somatropin showed that the RMP of the biosimilar presented three additional highly clinically relevant safety concerns compared with its originator Genotropin (i.e. 'new neoplasm', 'intracranial aneurysm' and 'intracranial haemorrhage').
The originator SmPC-biosimilar SmPC comparison performed as a sensitivity analysis showed one additional MedDRA term not identified in the main analyses concerning filgrastim products (Appendix III). The SmPC of the filgrastim originator presented 'glomerulonephritis', whereas the biosimilar SmPCs did not. In the case of erythropoietin products, two biosimilars reported two potentially serious adverse events ('cerebral haemorrhage', 'aneurysms') and three nonserious ones ('weakness', 'dizziness', 'tiredness') not reported in the originator SmPC. The SmPCs of infliximab biosimilars listed more types of neoplasm than the originator SmPC. Comparisons between other active substances showed no further differences.
Discussion

Summary of main findings
There is a negligible number of differences concerning information on the safety profiles of biosimilars and their corresponding originators, as reported in the publicly available regulatory documents. Most differences were found for infliximab medicinal products. The originator (Remicade) included in the RMP two general safety concerns (i.e. 'interstitial lung disease' and 'interaction with drugs') not mentioned in the RMP of the biosimilars, while the biosimilar RMPs presented three general safety concerns (i.e. 'bowel obstruction', 'haematological reactions' and 'lack of efficacy') not mentioned in the RMP of the originator.
The qualitative comparisons of general safety concerns for other active substances showed only one difference or none. Overall, none of the differences was related to immunogenicity.
Interpretation of results
Similarity between biosimilars and originators should be demonstrated at the time of authorization for both efficacy and safety, and regulatory documents (RMPs, SmPCs) are continuously updated during the life cycle of the products, so we expected to find no major differences in the available safety information reported. Our study confirmed that information about the safety of biosimilars and originators was reported consistently across the regulatory documents. During drug life cycle management, it is expected that the differences that occur between biosimilars and originators are those linked to the production process (e.g. immunogenicity), and they may lead to less frequent and serious adverse events [29] . However, we found that immunogenicity was reported in the safety profile for each biological medicinal product (despite the various manufacturing processes). This confirms that immunogenicity is not an exclusive risk for biosimilars. Table 2 Clinical relevance classification of general safety concerns We also tried to provide further explanations for the remaining few observed differences. The regulatory safety information for infliximab biosimilars and their originator showed differences, especially on a quantitative level (i.e. counting the various safety concerns contained for each general safety concern). However, the safety concerns of the infliximab originator and of the biosimilars share the same origins but are otherwise specified (e.g. 'Merkel cell carcinoma and melanoma' for originator vs. 'skin cancer' for biosimilars).
Few differences emerged from the comparison of RMPs of biosimilars with the SmPC of the originator. In the case of somatropin, the biosimilar (Omnitrope) reported 'new neoplasm', 'intracranial aneurysm and intracranial haemorrhages' as potential risks reported in the RMP which were not shared by the SmPC of the originator (Genotropin) [30] [31] [32] . This discrepancy has an explanation; in fact, this risk was the result of the French Safety and Appropriateness of Growth hormone treatments (SAGhE) study, which triggered an EMA referral procedure, resulting in the decision to present an RMP for the originator also containing the above-mentioned risks (although it is not publicly available, as it has not been approved centrally) [30, 33, 34] .
The regulatory documents of Eprex, Silapo and Retacrit specified the risk of pure red cell aplasia only with subcutaneous administration in renal patients. The other erythropoietin biosimilars did not specify this and were not registered for subcutaneous use in these patients [35] [36] [37] . As a conclusion, the safety profile also considers different administration routes in addition to the various indications of the biosimilars.
Specific differences also emerged for filgrastim biosimilars. For example, the potential risk of cytokine release syndrome was only established with the use of Accofil (filgrastim) in the RMP. However, this particular safety concern follows a PRAC decision published on 11 April 2013, valid for all the MAHs of filgrastim [38] . This means that in the near future, with periodic RMP updates, differences will be further reduced.
Strengths and limitations
The present study used official publicly available regulatory documents in which all safety information is collected about the biosimilars and corresponding originators analyzed. Comparisons between biosimilar RMPs and originator SmPCs were affected by heterogeneous terminology (meaning that different words are used to describe the same concept, as Figure 1 (A) Frequency of safety concerns contained in each single general safety concern in the summaries of risk management plans (RMPs) and documents for procedural steps taken and scientific information after the authorization of insulin glargine products (safety concerns of biosimilars were grouped and biosimilars are presented as a category). (B) Frequency of safety concerns contained in each single general safety concern in the summaries of RMPs and documents for procedural steps taken and scientific information after the authorization of infliximab products (safety concerns of biosimilars were grouped and biosimilars are presented as a category). H, high clinical relevance; L, low clinical relevance; M, medium clinical relevance; * = originator; Biosimilars (n), number of biosimilars that are grouped detailed in Appendix I). However, the results of the originator SmPC-biosimilar SmPC comparison performed as a sensitivity analysis confirmed the overall consistency in safety information reported.
The publication of the 'Procedural steps taken and scientific information after authorization' document was not aimed at updating the RMP, and it also fueled further heterogeneity. Additionally, few updated RMPs were available, which resulted in more data extraction from the 'Procedural steps taken and scientific information after authorization' documents themselves. To reduce heterogeneity, the safety concerns in regulatory documents could be harmonized by using standard terminology (e.g. MedDRA or World Health Organization -Adverse Reactions Terminology). Additionally, the heterogeneity in presenting nonspecific vs. specific safety concerns (e.g. 'autoimmune events' vs. 'systemic lupus erythematosus') can also be avoided. Nonspecific safety concerns valid for particular pharmacodynamics could be 'imposed' in all RMPs. In the example of infliximab, 'opportunistic infections' could be stated as a potential risk that always needs to be assessed.
In principle, the safety concerns can be resolved over time with continuous life cycle product management which is dynamic in nature. However, an RMP is updated after a request from a national competent authority or when the benefit-risk ratio is changed significantly [39] . Additionally, earlier research on RMP development showed that identified risks are seldom removed from an RMP [40] .
In our study, using the regulatory documents publicly available at the time of the analysis, the resolved safety concerns could not be identified systematically. However, we found only two (out of 21) RMPs updated, so the risk of not considering a removed safety concern was minimized.
It is understandable that a thorough RMP update in line with regulatory requirements takes time and is therefore Figure 2 (A) Frequency of safety concerns contained in each single general safety concern in the summaries of risk management plans (RMPs) and documents for procedural steps taken and scientific information after the authorization of erythropoietin biosimilars or the Summary of Product Characteristics (SmPC) of erythropoietin originator (safety concerns of biosimilars were grouped and biosimilars are presented as a category). (B) Frequency of safety concerns contained in each single general safety concern in the summaries of RMPs and the documents for procedural steps taken and scientific information after the authorization of somatropin biosimilar or the SmPC of somatropin originator (safety concerns of biosimilars were grouped and biosimilars are presented as a category). (C) Frequency of safety concerns contained in each single general safety concern in the summaries of RMPs and the documents for procedural steps taken and scientific information after the authorization of filgrastim biosimilars or the SmPC of filgrastim originator (safety concerns of biosimilars were grouped and biosimilars are presented as a category). (D) Frequency of safety concerns contained in each single general safety concern in the summaries of RMPs and the documents for procedural steps taken and scientific information after the authorization of follitropin-alfa biosimilars or the SmPC of follitropin-alfa originator (safety concerns of biosimilars were grouped and biosimilars are presented as a category). H, high clinical relevance; L, low clinical relevance; M, medium clinical relevance; PWS, Prader-Willi syndrome; * = originator; Biosimilars (n), number of biosimilars that are grouped done infrequently [40] . Regular RMP updates may be made mandatory, to avoid delays in the publication of new information available.
According to the EMA, the safety profile of a drug can be influenced by different study designs and populations, which justifies the evolution of RMPs independently for each specific product, even though medicinal products contain the same active substance [41] . However, a safety concern occurring more frequently with a specific study design and population could also emerge earlier owing to a higher level of use. With the current policy of adding safety concerns to the RMP, it is likely that rare adverse reactions will stay undetected for products which are used less often. Therefore, it is appropriate to add each established safety concern to the RMP for each biological medicinal product with the same active substance, as a potential risk [39] . This policy for updating an RMP is already applied by the PRAC.
The safety concerns that are not shared between biosimilars and originators, and become a safety signal require additional direct comparisons through postmarketing effectiveness and safety studies, which can be promoted both by MAHs and public research institutions. Future research should investigate whether reported safety concerns have led to differential additional risk minimization measures or post-authorization safety studies between biosimilars and originators.
Although our study showed that safety information reported in the official regulatory documents is reported consistently both for biosimilar and originators, a direct comparison between biosimilars and related originators through formal postmarketing studies (observational or clinical trials) is mandatory for specific safety and effectiveness issues emerging during the products' life cycle.
The present study included the first cohort of biosimilars approved until 1 November 2015. The approval scenario for biosimilars is dynamic, and during the last months new biosimilars were approved in the EU for five INNs (etanercept, enoxaparin sodium, teriparatide, rituximab and adalimumab). These new biosimilars were not part of our analysis of first biosimilars, and the results cannot be extrapolated to these drugs.
Promoting biosimilar use
The risks of low clinical relevance include the unknown effects of use in specific populations and long-term use, and interactions with other drugs. The nature of these safety concerns is precautionary -i.e. it is inappropriate to exclude them a priori from the safety profile, and is therefore valid for biosimilars as well as originators. Such differences should have little impact on the prescribing choices between an originator and a biosimilar.
Some differences emerged when comparing infliximab originator with its biosimilars. However, it should be noted that infliximab showed the majority of general safety concerns (14 general safety concerns) of all analyzed substances. On a qualitative level, the originator (Remicade) presented two (out of 14) general safety concerns of high, and one of low clinical relevance that were not mentioned by the RMP of its biosimilars, while the biosimilars presented three general safety concerns of medium clinical relevance which were not mentioned in the originator RMP. This suggests that, in general, further postmarketing research is warranted for infliximab (both originator and biosimilars). Although the analysis suggests variance in safety information, a systematic review showed similar safety outcomes between biosimilars and originator [42] .
Conclusion
Based on the currently available official information filed for regulatory purposes at EMA level, no substantial differences were observed in the reporting of safety information on biosimilars and related originators. Some differences were found between infliximab biosimilars and originator, but only one was considered to be a highly clinically relevant safety issue. Immunogenicity was reported in the safety information for each product considered, for biosimilars and originators alike.
Although similarity has been shown in licensed biosimilars, a direct comparison between biosimilars and related originators through formal postmarketing studies (observational or clinical trials) remain important to evaluate specific safety and effectiveness issues emerging during the products' life cycle.
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Appendix 1
Overview of grouping process of the terms retrieved in the regulatory documents into a general safety concern
The grouping was conducted combining single safety concerns (with similar origin with regard to the type of event) into a unique general safety concern. The number reported in the 'General safety concern' column, listed after the term, indicates the number of autonomous safety concerns contained by the general safety concern.
Safety concerns as reported in summary of the RMP General safety concern Erythropoietins Pure red cell aplasia (PRCA) PRCA, 2
Increased risk of PRCA with subcutaneous administration in renal failure patients Tumour growth potential Neoplasm, 2
Increased mortality (cancer patients)
Relatively high target haemoglobin concentrations Thrombotic vascular events, 2
Thrombotic vascular events
General safety and long-term use General safety and long-term use, 2
Potential off-label use regarding s.c. application in renal anaemia patients in respect of missing comparative data on safety and immunogenicity between HX575 and Erypo in these patients 
Appendix IIa
Comparison of general safety concerns extracted from summaries of risk management plans (RMPs) and documents for procedural steps taken and scientific information after the authorization of medicinal products
Boxes containing an 'x' indicate that the general safety concern is found in the summary of the RMP or document for procedural steps taken and scientific information after the authorization. Safety concerns (green background) that had similar descriptions were combined to a general safety concern (white background) as indicated in Appendix I. The originator is indicated with an asterisk. A date after the safety concern indicates that the safety issue is established in the document for procedural steps taken and scientific information after the authorization, and signifies when the risk was established.
(continues) Safety information of biosimilars vs. their originators in EU RMPs
